Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CGTX | PRESS-RELEASE | neutral | 2/10 | Cognition Therapeutics announced its CEO will present at the Jefferies Global Healthcare Conference (June 4) and H.C. Wa | Jun 1, 2026 |
| NTLA | PRESS-RELEASE | neutral | 5/10 | Intellia Therapeutics announced that Phase 3 HAELO trial data for lonvo-z (NTLA-2002) in hereditary angioedema will be p | Jun 1, 2026 |
| TGTX | PRESS-RELEASE | bullish | 5/10 | TG Therapeutics published a post-hoc pooled analysis of Phase 3 ULTIMATE I/II data in Frontiers in Immunology, showing B | Jun 1, 2026 |
| IVVD | PRESS-RELEASE | bullish | 5/10 | Invivyd completed enrollment in the Phase 3 DECLARATION trial evaluating VYD2311 for prevention of symptomatic COVID-19. | Jun 1, 2026 |
| AGIO | PRESS-RELEASE | mixed | 6/10 | Agios Pharmaceuticals licensed exclusive global rights to cevidoplenib, a next-generation oral SYK inhibitor for immune | Jun 1, 2026 |
| BIIB | PRESS-RELEASE | mixed | 5/10 | Biogen and UCB announced publication of full Phase 3 PHOENYCS GO results for dapirolizumab pegol (DZP) in The Lancet, sh | Jun 1, 2026 |
| IMTX | PRESS-RELEASE | bullish | 6/10 | Immatics presented extended Phase 1 data for its TCR bispecific IMA401 at ASCO 2026, showing a 29% confirmed ORR and 64% | May 31, 2026 |
| RVMD | PRESS-RELEASE | bullish | 8/10 | Revolution Medicines reported overwhelmingly positive Phase 3 data for daraxonrasib in metastatic pancreatic cancer, sho | May 31, 2026 |
| REPL | PRESS-RELEASE | bullish | 6/10 | Replimune presented final Phase 1 data for RP2 (alone and with nivolumab) at ASCO 2026, showing durable responses in hea | May 31, 2026 |
| IMCR | PRESS-RELEASE | bullish | 6/10 | Immunocore presented updated Phase 1 data for brenetafusp in heavily pretreated advanced melanoma at ASCO 2026, showing | May 31, 2026 |
| EIKN | PRESS-RELEASE | neutral | 5/10 | Eikon Therapeutics presented updated Phase 2 data for EIK1001 (TLR7/8 agonist) in first-line NSCLC at ASCO 2026, showing | May 30, 2026 |
| BNTX | PRESS-RELEASE | bullish | 7/10 | BioNTech and BMS announced positive interim Phase 2 data for pumitamig (PD-L1xVEGF bispecific) plus chemotherapy in firs | May 30, 2026 |
| MLYS | PRESS-RELEASE | bullish | 7/10 | Mineralys Therapeutics presented positive post-hoc data from the Phase 3 Launch-HTN trial at ESH 2026, showing lorundros | May 30, 2026 |
| IMTX | PRESS-RELEASE | bullish | 7/10 | Immatics reported updated Phase 1 data for IMA203CD8 PRAME cell therapy at ASCO 2026, showing 63% ORR (50% cORR) in heav | May 30, 2026 |
| REPL | PRESS-RELEASE | bullish | 8/10 | Replimune presented 3-year landmark overall survival data from the IGNYTE trial of RP1 plus nivolumab in anti-PD-1-faile | May 30, 2026 |
| COGT | PRESS-RELEASE | bullish | 8/10 | Cogent Biosciences reported highly positive Phase 3 PEAK trial results for bezuclastinib in combination with sunitinib i | May 30, 2026 |
| CELU | PRESS-RELEASE | bearish | 6/10 | Celularity disclosed a Nasdaq late filing notice for its overdue Q1 2026 10-Q. The delayed filing triggers a 60-day cure | May 29, 2026 |
| RXRX | PRESS-RELEASE | neutral | 2/10 | Recursion Pharmaceuticals granted inducement RSU awards covering ~2.99 million shares to 33 new employees under its 2024 | May 29, 2026 |
| OCS | PRESS-RELEASE | bearish | 7/10 | Oculis announced that its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 in diabetic macular edema (DME) failed to me | May 29, 2026 |
| MNKD | PRESS-RELEASE | bullish | 8/10 | MannKind received FDA approval for Afrezza® in children and adolescents aged 6+. This expands the addressable patient po | May 29, 2026 |
| MNKD | PRESS-RELEASE | bullish | 8/10 | MannKind announced FDA approval of Afrezza (inhaled insulin) for pediatric patients aged 6+ with type 1 and type 2 diabe | May 29, 2026 |
| CMND | PRESS-RELEASE | neutral | 3/10 | Clearmind Medicine announced a Japanese patent application for its MEAI-based depression treatment, expanding its IP por | May 29, 2026 |
| OPTH | PRESS-RELEASE | bullish | 6/10 | Optimi Health acknowledged the TGA's final recommendations expanding Australia's Authorized Prescriber scheme for psiloc | May 29, 2026 |
| REPL | PRESS-RELEASE | bullish | 8/10 | Replimune announced alignment with the FDA on a path forward for resubmission of the RP1 BLA for advanced melanoma, with | May 29, 2026 |
| TPST | PRESS-RELEASE | bearish | 6/10 | Tempest Therapeutics announced a warrant exercise agreement to immediately raise ~$2M in gross proceeds by reducing the | May 29, 2026 |
| SABS | PRESS-RELEASE | neutral | 3/10 | SAB Biotherapeutics announced upcoming data presentations at the ADA and FOCIS conferences in June 2026, highlighting it | May 29, 2026 |
| AGIO | PRESS-RELEASE | bearish | 6/10 | Agios Pharmaceuticals announced it will not advance tebapivat, its next-generation oral PK activator, in lower-risk myel | May 29, 2026 |
| PHVS | PRESS-RELEASE | neutral | 4/10 | Pharvaris announced the acceptance of 8 abstracts (1 oral, 7 flash talk/poster) at the EAACI 2026 congress, including Ph | May 29, 2026 |
| ALLO | PRESS-RELEASE | neutral | 3/10 | Allogene Therapeutics announced a planned CEO transition: Dr. David Chang will step down as President and CEO effective | May 28, 2026 |
| OTLK | PRESS-RELEASE | bearish | 7/10 | Outlook Therapeutics announces a $5.0M registered direct offering of 8.54M shares at $0.5855/share to its largest stockh | May 28, 2026 |